Activity Description
Clinicians would attest to reviewing the patients’ history of controlled substance prescription using state prescription drug monitoring program (PDMP) data prior to the issuance of a Controlled Substance Schedule II (CSII) opioid prescription lasting longer than 3 days. For the transition year, clinicians would attest to 60 percent review of applicable patient’s history. For the Quality Payment Program Year 2 and future years, clinicians would attest to 75 percent review of applicable patient’s history performance.
| Activity ID | Activity Weighting | Sub-Category Name |
|---|---|---|
| IA_PSPA_6 | High | Patient Safety and Practice Assessment |
| Activity ID | Activity Weighting | Sub-Category Name |
|---|---|---|
| IA_PSPA_6 | High | Patient Safety and Practice Assessment |